Investigating complex congenital heart defects in fetuses using multi-omics techniques
Official title: Antenatal Investigation of Fetuses With Complex Congenital Heart Defects Using multiOMICS
Run by University Hospital, Bordeaux · NCT06705543 · Data updated 2026-11-12
This study is trying to find out what causes complex heart defects in unborn babies by looking at their genetic and environmental factors using samples from amniotic fluid.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | Women only |
| Enrollment | 40 (estimated) |
| Sponsor | University Hospital, Bordeaux Academic / other |
| Locations | 2 sites (Bordeaux and 1 other locations) |
| Status | Recruiting |
| Started | April 1, 2025 |
| Main results expected | June 2026 |
| Study ends | December 2026 |
| Registry record updated | April 10, 2025 |
| Trial ID | NCT06705543 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are pregnant women aged 18 and older carrying a single fetus diagnosed with a complex non-syndromic congenital heart defect, without identified chromosomal abnormalities.
✕Probably not a fit
Patients with syndromic congenital heart defects or those whose fetuses have identified chromosomal abnormalities or infections may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to explore the underlying causes of complex congenital heart defects (CHD) in fetuses by employing a multi-omics approach, which includes exome sequencing, RNA sequencing, and methylation analysis. The research focuses on identifying epigenetic factors that may contribute to these cardiac malformations, particularly in relation to environmental influences during pregnancy. By analyzing amniotic fluid samples, the study seeks to uncover the complex interplay between genetic and environmental factors that lead to CHD. The findings could enhance our understanding of the etiology of these defects and improve prenatal diagnostics.
Why it matters
Potential benefit: If successful, this study could lead to better identification of risk factors for congenital heart defects, potentially improving prenatal care and outcomes for affected fetuses.
How similar studies have gone: While the multi-omics approach is gaining traction, this specific application to complex congenital heart defects is relatively novel and has not been extensively tested in prior studies.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Fetuses with congenital heart disease : * Pregnant women aged 18 and more * Single foetal pregnancy in which the foetus has a complex non-syndromic congenital heart defect, with no identified chromosomal abnormality, gene syndrome or infection. * Patient for whom the indication for amniocentesis has been accepted by the CPDPN and accepted by the couple/patient * Gestational age between 20 and 28 weeks' gestation. * Person affiliated to or benefiting from a social security scheme. * Free, informed and express consent (confirmed in writing) (at the latest on the day of inclusion and before any examination required by the research). Control Population for RNAseq and MéthlySeq * Pregnant women aged 18 and more * Patient in whom the indication for amniocentesis has been retained by the CPDPN and accepted by the couple/patient, for a non-malformative ultrasound anomaly (hyperechoic bowel, idiopathic hydramnios, increased risk of trisomy 21, agenesis of the OPN, suspected toxoplasmosis/CMV seroconversion), with no chromosomal anomaly, gene syndrome or infection identified. * Gestational age between 20 and 28 weeks' gestation. * Person affiliated to or benefiting from a social security scheme. * Free, informed and express consent (confirmed in writing) (at the latest on the day of inclusion and before any examination required by the research). Exclusion Criteria: For both populations (cases and controls) : * Female minors, * Patients not affiliated to the social security system, * Patients who do not understand French, * Patients under guardianship * Multiple pregnancies, or where the foetus has associated malformations
Where it's running
-
CHU de Bordeaux
Bordeaux, France Recruiting -
CHU de Nantes
Nantes, France Not yet recruiting
Study contacts
- Principal investigator: Caroline ROORYCK-THAMBO, PROF — University Hospital, Bordeaux
- Study coordinator: Caroline ROORYCK-THAMBO, PROF
- Email: caroline.rooryck-thambo@chu-bordeaux.fr
- Phone: +335 56 79 59 81
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Adapting and testing PEN-Plus in Zambian primary care
Aiming to see if the PEN-Plus package can be adapted and used in two Zambian hospitals to better manage chronic diseases like heart disease, diabetes, hypertension, and sickle cell in primary care.
-
Wireless NIRS Sensor Use in the NICU for Monitoring on Neonates
A wireless NIRS sensor is tested on infants in the NICU to see how well it stays on and how it notes brain signals when used alongside standard wired sensors.
-
Screening for lipid disorders in children and teens with chronic diseases to flag cardiovascular risk
This study tests a blood test and a questionnaire to screen children and teens with chronic conditions for lipid metabolism disorders and familial hyperlipidemia.
-
Prehabilitation before heart surgery for adults with congenital heart disease
This study is testing whether a tailored, supervised exercise program before heart surgery helps adults with congenital heart disease perform better and improve fitness.
-
Accessible care model comparing nurse-led versus physician-led transition education for teens and young adults with congenital heart disease
This project will test whether an accessible care model and nurse-led versus physician-led transition education helps teens and young adults (ages 12–26) with congenital heart disease move successfully from pediatric to adult heart care.
-
Surgical techniques and outcomes across the lifespan in congenital heart disease in China
See which surgical factors and care patterns affect recovery after heart surgery for people with complex congenital heart disease in China.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.